c-Met/HGFR Inhibitor

c-Met/HGFR Inhibitors (229):

Art. -Nr.	Produktname	Wirkung	Reinheit

HY-170954

C-Met/Axl-IN-1	Inhibitor
C-Met/Axl-IN-1 (Compound 22a) is an orally active and selective type II c-Met/Axl inhibitor with IC₅₀ values of 1 nM and 10 nM, respectively. C-Met/Axl-IN-1 can inhibit proliferation, induce cell cycle arrest and apoptosis of tumor cells. C-Met/Axl-IN-1 has strong anti-tumor activity.

HY-149511

MET/PDGFRA-IN-2	Inhibitor
MET/PDGFRA-IN-2 (compound 8h) is a MET and PDGFRA protein inhibitor. MET/PDGFRA-IN-2 induces cell apoptosis. MET/PDGFRA-IN-2 inhibits proliferation of MET-positive cells (IC₅₀s: 9.7, 6.1, 12.0, 11.5, 8.6, 34.4 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively).

HY-153831

c-Met-IN-17	Inhibitor
c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research.. c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P992464

SHR-A1403 Antibody	Inhibitor
SHR-A1403 Antibody is an anti-c-Met monoclonal antibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma.

HY-15268

PP487	Inhibitor
PP487 is a selective dual inhibitor of Tyrosine kinase/PI3-K, with IC₅₀ values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. PP487 can be used in cancer research.

HY-162868

c-Met/HDAC-IN-4	Inhibitor
c-Met/HDAC-IN-4 is a dual inhibitor of c-Met/HDAC. The IC₅₀ value of c-Met/HDAC-IN-4 for c-Met is 28.92 nM. c-Met/HDAC-IN-4 can induce G₀/G₁ phase cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells, and it inhibits the proliferation and invasion of breast cancer cell lines.

HY-180834

Tyrosine kinase-IN-11	Inhibitor	98.75%
Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor. Tyrosine kinase-IN-11 decreases general tyrosine kinase activity, selectively inhibits PDGFR-β, SRC, and c-MET kinases. Tyrosine kinase-IN-11 induces apoptosis, accompanied by reduced ERK signalings. Tyrosine kinase-IN-11 exhibits selective anticancer activity against pancreatic cancer and renal cancer.

HY-143463

AC-386	Inhibitor
AC-386 is a highly potent c-Met inhibitor with IC₅₀ value of 7.42 nM. AC-386 has antiproliferative activities against certain cancer cell lines. AC-386 can be used for researching anti-cancer resistance.

HY-161141

EGFR/c-Met-IN-2	Inhibitor
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity.

HY-183672

c-Met-IN-28	Inhibitor
c-Met-IN-28 is a type III allosteric inhibitor of c-MET, with pK_i values of 7.4 (WT) and 7.1 (D1228V), and IC₅₀ values of 37 nM (WT) and 72 nM (D1228V) against human c-MET. c-Met-IN-28 can be used for research on c-MET-driven cancers.

HY-150576

c-Met-IN-13	Inhibitor
c-Met-IN-13 is a potent c-Met inhibitor with an IC₅₀ value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer.

HY-147694

c-Met-IN-11	Inhibitor
c-Met-IN-11 (compound 3) is a potent c-MET and VEGFR-2 inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively.

HY-152852S

Mefatinib-d₆	Inhibitor
Mefatinib-d6 free base (Mifanertinib-d6) is the deuterium labeled Mefatinib. Mefatinib is a potent tyrosine kinase inhibitor with antineoplastic activity.

HY-179034

CAIX/XII-IN-16	Inhibitor
CAIX/XII-IN-16 (Compound 5d) is a selective inhibitor of CA IX/XII and c-Met. CAIX/XII-IN-16‘s K_i values for hCA IX, hCA XII and CA I are 10.6, 31.8 and 2361 nM respectively, and its IC₅₀ value for c-Met is 0.49 μM. CAIX/XII-IN-16 exhibits significantly enhanced cytotoxicity against colon cancer cells under hypoxic conditions. CAIX/XII-IN-16 causes cell cycle arrest and induces apoptosis (apoptosis). CAIX/XII-IN-16 significantly enhances the efficacy of Oxaliplatin (HY-17371) and 5-Fluorouracil (HY-90006). CAIX/XII-IN-16 can be used for studies on chemotherapy resistance related to hypoxia.

HY-146884

MET kinase-IN-3	Inhibitor
MET kinase-IN-3 (compound 8) is an orally active and potent MET inhibitor, with an IC₅₀ of 9.8 nM. MET kinase-IN-3 shows good and broad-spectrum antiproliferative activity against cancer cell lines.

HY-161372

PARP1/c-Met-IN-1	Inhibitor
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for PARP1 and c-Met, with IC₅₀s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice.

HY-179098

Multi-target kinase-IN-8	Inhibitor
Multi-target kinase-IN-8 (3d) is an anti-cancer agent. Multi-target kinase-IN-8 exhibits inhibitory activity against various protein kinases (B-Raf V600E (IC₅₀ = 0.078 µg/mL), c-Met (IC₅₀ = 0.405 µg/mL), Pim-1 (IC₅₀ = 1.053 µg/mL), EGFR WT (IC₅₀ = 0.177 µg/mL), VEGFR-2 (IC₅₀ = 0.275 µg/mL)). Multi-target kinase-IN-8 can induce cell cycle arrest and promote early and late apoptosis. Multi-target kinase-IN-8 is commonly used in cancer research.

HY-149675

VEGFR-2/c-Met-IN-2	Inhibitor
VEGFR-2/c-Met-IN-2 (compound 3e) is a VEGFR-2/c-Met inhibitor, with IC₅₀ values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC₅₀: 3.403 µM).

HY-149880

c-Met-IN-18	Inhibitor
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20^e.c-Met-IN-18 can be used for the research of c-MET driven cancers. c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147575

Axl-IN-8	Inhibitor
Axl-IN-8 (NO.1) is a potent AXL inhibitor, with an IC₅₀ of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC₅₀ of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC₅₀ values of <10, 226.6 and 120.3 nM, respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.